BioRestorative Therapies (BRTX) Capital Expenditures (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Capital Expenditures came in at $79669.0 in Q4 2025, up 540.74% YoY from $12434.0 in Q4 2024, and up 118.87% on a QoQ basis from $36400.0 in Q1 2025.
BioRestorative Therapies (BRTX) Capital Expenditures (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 12 years of Capital Expenditures data on file, last reported at $79669.0 in Q4 2025.
- Quarterly Capital Expenditures rose 540.74% year-over-year to $79669.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $116069.0 (up 9.3% YoY) and the FY2025 annual result came in at $116069.0, up 9.3% from the prior year.
- Capital Expenditures advanced to $79669.0 in Q4 2025, from $36400.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $137674.0 in Q2 2022 to a low of -$24605.0 in Q3 2022.
- A 4-year average of $47037.4 and a median of $39490.5 in 2022 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2024 — Capital Expenditures tumbled 82.24% — and 2025, when it soared 540.74%.
- Tracing BRTX's Capital Expenditures over 4 years: stood at $42581.0 in 2022, then jumped by 64.45% to $70024.0 in 2023, then plunged by 82.24% to $12434.0 in 2024, then soared by 540.74% to $79669.0 in 2025.
- The last three Capital Expenditures figures came in at $79669.0 (Q4 2025), $36400.0 (Q1 2025), and $12434.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | BioRestorative Therapies | 1.94 Mn | -1.02 Mn | 17,964.00 | 79,669.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 79,669.00 |
| Dec 31, 2025 | 79,669.00 |
| Mar 31, 2025 | 36,400.00 |
| Mar 31, 2025 | 36,400.00 |
| Dec 31, 2024 | 12,434.00 |
| Dec 31, 2024 | 12,434.00 |
| Sep 30, 2024 | 58,459.00 |
| Sep 30, 2024 | 58,459.00 |
| Jun 30, 2024 | 6,050.00 |
| Jun 30, 2024 | 6,050.00 |
| Mar 31, 2024 | 29,246.00 |
| Mar 31, 2024 | 29,246.00 |
| Dec 31, 2023 | 70,024.00 |
| Dec 31, 2023 | 70,024.00 |
| Sep 30, 2023 | 11,948.00 |
| Sep 30, 2023 | 11,948.00 |
| Jun 30, 2023 | 29,049.00 |
| Jun 30, 2023 | 29,049.00 |
| Mar 31, 2023 | 60,022.00 |
| Mar 31, 2023 | 60,022.00 |